The interplay between WASH practices and vaccination with oral cholera vaccines in protecting against cholera in urban Bangladesh: Reanalysis of a cluster-randomized trial.
Chowdhury F. et al, (2023), Vaccine
Gene Signatures of Symptomatic and Asymptomatic Clinical-Immunological Profiles of Human Infection by Leishmania (L.) chagasi in Amazonian Brazil
da Matta VLR. et al, (2023), Microorganisms, 11, 653 - 653
A novel approach for estimating vaccine efficacy for infections with multiple disease outcomes: application to a COVID-19 vaccine trial
Williams LR. et al, (2023)
The effects of acute Methylene Blue administration on cerebral blood flow and metabolism in humans and rats
Singh N. et al, (2023), Journal of Cerebral Blood Flow & Metabolism, 0271678X2311579 - 0271678X2311579
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.
Moore SC. et al, (2023), Med (N Y)
Association between disease severity and co-detection of respiratory pathogens in infants with RSV infection
Lin G-L. et al, (2023)
Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.
Vatzia E. et al, (2023), NPJ Vaccines, 8
Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
Ulaszewska M. et al, (2023), Human Vaccines & Immunotherapeutics
Antibiotic spectrum index as an antimicrobial stewardship tool in paediatric intensive care settings
Zombori L. et al, (2023), International Journal of Antimicrobial Agents, 61, 106710 - 106710
Correction to: Febrile illness in high-risk children: a prospective, international observational study.
van der Velden FJS. et al, (2023), Eur J Pediatr, 182, 555 - 556
Cost-effectiveness of fractional doses of COVID-19 vaccine boosters in India
Du Z. et al, (2023), Med
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2
Szubert AJ. et al, (2023), eClinicalMedicine, 56
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.
Liu Z. et al, (2023), Gastroenterology, 164, 300 - 303.e3
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z. et al, (2023), Lancet Gastroenterol Hepatol, 8, 145 - 156
Long-term respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination
Mitsi E. et al, (2023)
Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.
Green C. et al, (2023), Clin Exp Immunol
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
EWER K., (2023), Clinical and Experimental Immunology
Polio eradication: Addressing the hurdles on the last mile
Thompson KM. et al, (2023), Cell, 186, 1 - 4
A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine.
Rajan M. et al, (2023), Pediatr Infect Dis J, 42, 66 - 73
A tool for evaluating heterogeneity in avidity of polyclonal antibodies.
Li K. et al, (2023), Front Immunol, 14